The News
CropDesign appoints new CEO
23/12/2004
GENT, BELGIUM, December 23, 2004 – CropDesign N.V. is pleased to announce that Dr. Johan Cardoen, formerly Vice-President Business Development, has been appointed Chief Executive Officer of the Company, replacing Karl-Peter Schlichting.
Johan Cardoen has been with CropDesign since 1999 and has spent over 16 years of his career in the Agricultural Biotechnology business with leading companies such as Plant Genetic Systems, Hoechst Schering AgrEvo GmbH and Aventis CropScience, holding various management positions in IP, Technology Acquisition and Business Development.
Dr. Pol Bamelis, Chairman of CropDesign says: “I would like to thank Dr. Karl-Peter Schlichting, previous CEO of CropDesign, for his commitment and dedication. Karl-Peter has been instrumental in steering the Company through a very successful financing round, which has now put the Company on a much stronger financial and strategic footing. CropDesign has made significant progress over the last year, and it has a growing and exciting pipeline of yield-enhancement traits, which have now also been validated in field trials. With the recent capital increase, together with substantial revenues generated from various deals, the Company is very well positioned to pursue the best possible route towards product development. Johan has a broad industry network and his deal-making expertise will prove to be a key asset for the company in the near future.”
CropDesign uses its rice TraitMill applied genomics platform to discover traits for the improvement of corn, rice and other cereal crops in both in-house and partnered programs. The company’s proprietary lead and field-validated lead pipeline is focused on enhancing yield and improving tolerance to drought and nutrient stress.
For further information, please contact: Antonella Masariè CropDesign N.V. Tel: +32 9 242 91 61 Fax: +32 9 241 50 89 E-mail: antonella.masarie@cropdesign.com
2004
- 21/01/2004
- 21/01/2004
- 28/01/2004
- 26/01/2004
- 26/01/2004
- 29/01/2004
-
29/01/2004
Sofinnova Partners investit dans InfraWorlds, société à fort potentiel
- 09/02/2004
- 09/02/2004
- 16/02/2004
- 25/02/2004
- 25/02/2004
-
26/02/2004
Esmertec gains a worldwide leadership role in fast growing mobile Java™ markets
- 24/02/2004
- 24/02/2004
-
23/02/2004
SOFINNOVA earmarks €85 million to accelerate activity in European wireless market
- 04/03/2004
- 08/03/2004
- 17/03/2004
- 08/03/2004
- 18/03/2004
- 29/03/2004
- 29/03/2004
-
07/04/2004
Esmertec™ provides Time Warner Cable with JVM solution for the OCAP Market
- 06/04/2004
- 06/04/2004
- 20/04/2004
- 21/04/2004
- 27/04/2004
-
03/05/2004
Vidiom Systems Selects Esmertec™ to provide the JVM solution for its OCAP Products
-
05/05/2004
Georges Haas, Ph.D., Joins Ingenium’s Supervisory Board Munich, Germany, May 5, 2004
-
10/05/2004
Faust raises 16 million euros to further develop its product candidates
-
10/05/2004
Faust Pharmaceuticals lève 16 M d’euros pour développer ses produits en clinique
-
03/05/2004
Saegis Pharmaceuticals Begins Phase II Clinical Trial of SGS742 for Alzheimer’s Disease
- 28/04/2004
-
12/05/2004
Ingenium Acquires Pivotal Patents for INGENOtypingTM Platform
-
17/05/2004
Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising
- 19/05/2004
- 25/05/2004
- 10/06/2004
- 07/06/2004
- 22/06/2004
- 07/06/2004
- 14/06/2004
-
14/06/2004
TRISENOX® Produces Hematologic Responses in 27 Percent of MDS Patients
-
22/06/2004
Esmertec to demonstrate new breakthrough Java™ Solution – Jbed™ Advanced during JavaOne 2004
- 22/06/2004
-
28/06/2004
Esmertec’s Java™ Virtual Machine (JVM) solution for mobile phones is selected by Panasonic
- 01/07/2004
- 23/06/2004
-
06/07/2004
Atomz Named to Second-Annual AlwaysOnTM List of Top 100 Private Companies
- 30/06/2004
-
12/07/2004
Qosmos reçoit un premier tour de financement de Sofinnova Partners
-
12/07/2004
Qosmos receives a first round of financing from Sofinnova Partners
-
07/07/2004
Esmertec ouvre un centre d'assistance clientèle et de test à Taipei (Taiwan)
-
07/07/2004
Esmertec is opening Customer Support and Testing Centre in Taipei, Taiwan
-
19/07/2004
Ablynx and Procter&Gamble form nanobody drug discovery and development partnership
- 22/07/2004
- 20/07/2004
-
22/07/2004
Esmertec welcomes Michel Bon, Former CEO and Chairman of France Telecom, to its Board
-
26/07/2004
Cell Therapeutics, Inc. Completes Enrollment in Third Pivotal Trial of XYOTAX™ in Lung Cancer
- 26/07/2004
-
28/07/2004
Diatos Elected Among the Top 15 Emerging Biotech Companies of 2004
-
30/07/2004
6WIND emporers customers and partners with a further commitment to quality
-
02/08/2004
Les plus hautes performances Java jamais atteintes sur cœur de MIPS32 24Kc
-
02/08/2004
Highest Java™ Performance Achieved by the MIPS32® 24Kc™ Core
- 27/07/2004
- 27/07/2004
- 16/08/2004
-
09/08/2004
"Euronext n'a pas la place financière qu'il mérite" Jean-Bernard Schmidt - Les Echos 9 Août 2004 -
-
30/08/2004
Tony Reis, l’ancien CEO de Swisscom, rejoint le Conseil d’Administration d’Esmertec
-
30/08/2004
Tony Reis, Former CEO of Swisscom, joins Esmertec’s Board of Directors
-
24/08/2004
Enfora partners with Esmertec to enable wireless Java technology in their GSM/GPRS OEM devices
-
24/08/2004
Enfora se rapproche d’Esmertec pour intégrer la technologie Java dans ses terminaux GSM/GPRS
-
16/08/2004
Intransa secures twenty five million dollars in series D funding
-
06/09/2004
Sensitive Object secures 2 million € Series A financing round from Sofinnova Partners
- 06/09/2004
-
08/09/2004
Oxxius reçoit un premier financement de 2,4 millions d'euros de Sofinnova Partners
-
14/09/2004
Le Dr Ulrich Schumacher rejoint le Conseil d’Administration d’Esmertec
-
08/09/2004
Oxxius receives 2.4 million euros from Sofinnova Partners in first round of financing
-
14/09/2004
Dr. Ulrich Schumacher joins Esmertec as a Member of the Board of Directors
- 20/09/2004
- 23/09/2004
-
23/09/2004
France Telecom selects Esmertec as technology partner for its embedded Java platforms
- 30/09/2004
- 30/09/2004
-
26/10/2004
Esmertec lève CHF 23.5 Millions par le biais d’obligations convertibles
-
26/10/2004
Esmertec raises CHF 23.5 Million from convertible note to fund growth
-
26/10/2004
Intransa annouces IP5500 - The industry's next-generation modular IP san solution for the mid-market
-
10/11/2004
Varioptic Selected Most Innovative Company of the Year for Its Liquid Lenses
-
10/11/2004
Varioptic élue Entreprise Innovante de l’année pour ses lentilles liquides
- 18/11/2004
-
18/11/2004
Esmertec Establishes Strategic Relationship with Mitsui & Co.
- 17/11/2004
-
22/11/2004
Ablynx appoints Edwin Moses as chairman of the board of directors
-
23/11/2004
Sendo choisit la solution Java d’Esmertec’s pour ses téléphones mobiles
-
23/11/2004
Sendo has chosen Esmertec’s Java solution for its mobile phones
- 23/11/2004
- 06/12/2004
-
05/12/2004
TRISENOX® Produces Hematologic Responses in 30 Percent of Patients with Higher-Risk MDS
-
09/12/2004
Esmertec to Integrate Hybrid’s OpenGL ES based Graphics Solutions into its Jbed Solution
-
16/12/2004
Diatos moves its lead drug, DTS-201, toward clinical trials in Europe
-
23/12/2004
CropDesign appoints new CEO
- 16/12/2004
- 01/11/2004
-
16/12/2004
Esmertec to further secure mobile Java content with SATSA-based implementation from Gemplus
-
16/12/2004
Esmertec sécurise les contenus des mobiles Java avec l’implémentation SATSA de Gemplus